国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

重組蛋白

產品名稱 貨號 規格
Recombinant Yersinia pseudotuberculosis serotype O:3 NADH-quinone oxidoreductase subunit H (nuoH), partial CSB-YP541786YAX
CSB-EP541786YAX
CSB-BP541786YAX
CSB-MP541786YAX
CSB-EP541786YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 UPF0303 protein YPK_1581 (YPK_1581) CSB-YP541787YAX
CSB-EP541787YAX
CSB-BP541787YAX
CSB-MP541787YAX
CSB-EP541787YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Phosphate acyltransferase (plsX) CSB-YP541788YAX
CSB-EP541788YAX
CSB-BP541788YAX
CSB-MP541788YAX
CSB-EP541788YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Protein dsrB (dsrB) CSB-YP541789YAX
CSB-EP541789YAX
CSB-BP541789YAX
CSB-MP541789YAX
CSB-EP541789YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 tRNA sulfurtransferase (thiI) CSB-YP541790YAX
CSB-EP541790YAX
CSB-BP541790YAX
CSB-MP541790YAX
CSB-EP541790YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Shikimate kinase 2 (aroL) CSB-YP541791YAX
CSB-EP541791YAX
CSB-BP541791YAX
CSB-MP541791YAX
CSB-EP541791YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Na (+)-translocating NADH-quinone reductase subunit D, partial CSB-YP541792YAX1
CSB-EP541792YAX1
CSB-BP541792YAX1
CSB-MP541792YAX1
CSB-EP541792YAX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Shikimate kinase 1 (aroK) CSB-YP541793YAX
CSB-EP541793YAX
CSB-BP541793YAX
CSB-MP541793YAX
CSB-EP541793YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Protein TusB (tusB) CSB-YP541794YAX
CSB-EP541794YAX
CSB-BP541794YAX
CSB-MP541794YAX
CSB-EP541794YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 50S ribosomal protein L16 (rplP) CSB-YP541795YAX
CSB-EP541795YAX
CSB-BP541795YAX
CSB-MP541795YAX
CSB-EP541795YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 50S ribosomal protein L5 (rplE) CSB-YP541796YAX
CSB-EP541796YAX
CSB-BP541796YAX
CSB-MP541796YAX
CSB-EP541796YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 50S ribosomal protein L35 (rpmI) CSB-YP541797YAX
CSB-EP541797YAX
CSB-BP541797YAX
CSB-MP541797YAX
CSB-EP541797YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase (arnC), partial CSB-YP541798YAX1
CSB-EP541798YAX1
CSB-BP541798YAX1
CSB-MP541798YAX1
CSB-EP541798YAX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Probable 4-amino-4-deoxy-L-arabinose-phosphoundecaprenol flippase subunit ArnF (arnF), partial CSB-YP541799YAX1
CSB-EP541799YAX1
CSB-BP541799YAX1
CSB-MP541799YAX1
CSB-EP541799YAX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Cysteine desulfuration protein sufE (sufE) CSB-YP541800YAX
CSB-EP541800YAX
CSB-BP541800YAX
CSB-MP541800YAX
CSB-EP541800YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Transcriptional regulator slyA (slyA) CSB-YP541801YAX
CSB-EP541801YAX
CSB-BP541801YAX
CSB-MP541801YAX
CSB-EP541801YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Alanine--tRNA ligase (alaS), partial CSB-YP541802YAX
CSB-EP541802YAX
CSB-BP541802YAX
CSB-MP541802YAX
CSB-EP541802YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Sulfate adenylyltransferase subunit 2 (cysD) CSB-YP541803YAX
CSB-EP541803YAX
CSB-BP541803YAX
CSB-MP541803YAX
CSB-EP541803YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 50S ribosomal protein L7/L12 (rplL) CSB-YP541804YAX
CSB-EP541804YAX
CSB-BP541804YAX
CSB-MP541804YAX
CSB-EP541804YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Iron--sulfur cluster insertion protein ErpA (erpA) CSB-YP541805YAX
CSB-EP541805YAX
CSB-BP541805YAX
CSB-MP541805YAX
CSB-EP541805YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質形式,可以通過多種方式產生大量蛋白質、修改基因序列和制造有用的商業產品。重組蛋白的技術資源在重組蛋白的開發過程中,除了表達系統之外,還面臨著一系列令人困惑的選擇,如表達載體的選擇、表達蛋白的長度(全長或部分)、是否帶標簽等。在生產重組蛋白時,你必須做出很多決定。如果你選擇的明智,你將獲得高質量的重組蛋白,后續的實驗更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質量和純度不符合要求。在這里,來自CUSABIO的蛋白表達工程師根據他們開發重組蛋白的經驗總結出了幾個有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產,在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產重組蛋白。

第二條:如何選擇合適的表達載體?

表達載體是一種DNA分子,它攜帶特定的基因進入宿主細胞,并利用細胞的蛋白質合成機制來產生由該基因編碼的蛋白質。表達載體可使外源基因在宿主細胞中高效表達,經過多年的發展,表達載體已成為一種成熟而受歡迎的生物技術。在重組蛋白生產過程中是一種基本成分。正如標題所示,本文主要總結了幾個有用的技巧來選擇合適的表達載體。

第三條:如何表達具有生物活性的蛋白質?

根據重組蛋白的不同應用,對其生物活性有不同的要求。但是我們如何確保蛋白質的產生具有生物活性呢?本文將圍繞這個主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.jhhuazhong.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達服務,您可以點擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質有任何疑問,涉及到蛋白質的價格、交貨、質量等,您可以點擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>